statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor...

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced that additional data from the ABACUS-1 trial has been...

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ('Kiora' or...

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX  Get Free Report) dropped 3.8% during mid-day trading on Thursday . The company traded as low as $0.58 and last traded at $0.58. Approximately 78,144...

Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 3.8%

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced the publication of results from a Phase 1 double-masked...

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kiora Pharmaceuticals price target lowered by $1.50 at H.C. Wainwright, here's why

Latest Ratings for KPRX
 DateFirmActionFromTo Jan 2022Maxim GroupInitiates Coverage OnBuy
 View More Analyst Ratings for KPRX

 View the Latest Analyst Ratings

read more...

HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million...

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Kiora Pharmaceuticals Inc trading resumes

Kiora to webcast investor conference call at 5:30 pm today; details belowEncinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ...

Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Volume	84,397.00
52-Wk High	$2.70
52-Wk Low	$0.4511

Period	Estimated	Reported	Surprise	Result
Q1'24	$0.28	--	--	N/A
Q4'23	-$0.39	--	--	N/A
Q3'23	-$0.52	--	--	N/A
Q2'23	-$1.07	-$0.79	25.82%	BEAT
Q1'23	-$1.56	--	--	N/A

KPRX Kiora Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals